STAT

AUGUST 16, 2024

  The Centers for Medicare & Medicaid Services released the Maximum Fair Prices (MFPs) for the first 10 drugs subject to negotiation under the Inflation Reduction Act. This is an important moment in prescription drug pricing policy. billion ) in 2026.

Drug Pricing 284

Drug Pricing Diabetes 284

STAT

SEPTEMBER 13, 2024

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Good morning, and congratulations on making it through another week. She is very likely the cutest and most relatable animal I’ve ever seen.

Diabetes 293

Diabetes Drug Pricing Drug Development 293

pharmaphorum

APRIL 13, 2022

The treatment has been around for over a century but insulin has still become the centre of the ongoing discussion over pricing of pharmaceutical products. Ben Hargreaves looks at why insulin’s price is so controversial and whether this could be set to change. In the US, approximately 37.3 In the US, approximately 37.3

Drug Pricing 130

Drug Pricing Diabetes Biosimilars 130

STAT

MAY 15, 2024

According to Yale researchers, 14% Americans who need insulin to control their diabetes spend more than 40% of their post-subsistence income (what is available after paying for food and housing) on the drug. Many avoid or ration their treatment because of the high cost.

Diabetes 312

Diabetes Drug Pricing 312

STAT

MARCH 29, 2024

Diabetes drugs are too expensive in the U.S., And blockbuster GLP-1 drugs, too, could be a lot less expensive, according to an investigation published this week in JAMA Network Open, with a simple change: robust generic competition. based on an estimate that factors in a 10% to 50% profit margin.

Diabetes 362

Diabetes Drug Pricing 362

STAT

OCTOBER 8, 2024

Food and Drug Administration for a “reckless and arbitrary” decision to remove a widely prescribed Eli Lilly drug for combating diabetes and obesity from an official shortages list. The FDA noted, though, that a rival drug from Novo Nordisk called Wegovy remains on the shortages list.

Compounding 350

Compounding Compounding Pharmacies Diabetes Drug Pricing 350

STAT

NOVEMBER 8, 2023

Eli Lilly’s blockbuster drug tirzepatide, sold as Mounjaro for type 2 diabetes, has been cleared to treat obesity, making it the second in a highly effective class of weight loss medications to enter the market.

Diabetes 363

Diabetes Drug Pricing 363

STAT

AUGUST 10, 2023

The company is riding a wave of sky-high demand for its highly effective diabetes and weight-loss drugs, Ozempic and Wegovy, but will extend the limits introduced for Wegovy supplies.  The news came as the drugmaker raised its full-year profit and sales forecasts for a second time.

Drug Pricing 232

Drug Pricing Diabetes 232

STAT

MAY 20, 2024

After a few victories he’s claimed — experts say some credit is deserved, but the full story is a bit more complicated — he’s now progressed to demanding that Novo Nordisk cut its price for its novel, wildly popular diabetes and weight-loss drugs. Sanders (I-Vt.)

Diabetes 348

Diabetes Pharmaceutical Companies Pharmaceutical Companies Vaccines 348

STAT

MAY 23, 2023

… Novo Nordisk disclosed that an oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity , STAT writes. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Drug Pricing 241

Drug Pricing Dosage Diabetes 241

STAT

JUNE 14, 2024

Bernie Sanders threatened to subpoena the company over its pricing of the popular diabetes drug Ozempic and the obesity drug Wegovy, the Senate health committee announced Friday. WASHINGTON — Novo Nordisk CEO Lars Fruergaard Jørgensen will testify before the Senate after Sen.

Diabetes 335

Diabetes Drug Pricing 335

STAT

SEPTEMBER 20, 2024

“Millions of Americans with diabetes need insulin to survive, yet for many of these vulnerable patients, their insulin drug costs have skyrocketed over the past decade thanks in part to powerful pharmacy benefit managers and their greed,” said Rahul Rao, Deputy Director of the FTC’s Bureau of Competition, in a statement.

Diabetes 363

Diabetes Drug Pricing 363

STAT

DECEMBER 6, 2023

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering.

Diabetes 301

Diabetes Drug Pricing 301

STAT

OCTOBER 10, 2024

billion deal in which Novo Nordisk’s parent foundation would acquire Catalent, a leading contract drug manufacturer, over concerns the acquisition would give the pharmaceutical company an unfair advantage in the burgeoning market for drugs used to treat obesity and diabetes.

Packaging 297

Packaging Diabetes Pharmaceutical Companies Pharmaceutical Companies 297

STAT

JUNE 11, 2024

division over the company’s pricing of the popular diabetes drug Ozempic and the obesity drug Wegovy, his office announced Tuesday. WASHINGTON — Senate health committee chair Bernie Sanders has called a vote to subpoena the chief of Novo Nordisk’s U.S. The vote is scheduled for June 18.

Diabetes 325

Diabetes Drug Pricing 325

STAT

MAY 2, 2024

Novo Nordisk defended the prices of its blockbuster diabetes and obesity drugs Ozempic and Wegovy amid a Senate probe into what the company charges.

Diabetes 323

Diabetes Drug Pricing 323

STAT

MAY 9, 2023

Bernie Sanders’ plans for drug pricing interrogations, he told STAT in an interview. WASHINGTON — Wednesday’s Senate hearing on high costs for insulin “is not the end” of Sen. But it will be a show.

Drug Pricing 246

Drug Pricing Diabetes 246

STAT

SEPTEMBER 24, 2024

WASHINGTON — Senate health committee chair Bernie Sanders said major drug middlemen have agreed not to limit coverage of Novo Nordisk’s Ozempic and Wegovy if the company lowers the prices of the treatments.

Diabetes 352

Diabetes Drug Pricing 352

STAT

SEPTEMBER 23, 2024

  Medicare doesn’t cover drugs used for weight loss, but Wegovy made the list because it is also approved to reduce major heart complications, according to the paper’s authors. Novo Nordisk makes the drugs, and Medicare is expected to negotiate prices of all three in the next round.

Specialty Pharmacies 335

Specialty Pharmacies Diabetes Drug Pricing 335

STAT

AUGUST 22, 2023

German drugmaker Boehringer Ingelheim is the latest pharmaceutical company to sue the federal government over a law that would allow Medicare to negotiate certain drug prices, Reuters reports. Continue to STAT+ to read the full story…

Vaccines 236

Vaccines Drug Pricing Diabetes Pharmaceutical Companies 236

STAT

OCTOBER 17, 2024

billion deal in which Novo Nordisk’s parent foundation would acquire Catalent, a leading contract drug manufacturer, over concerns the acquisition will harm competition and reduce patient access to popular diabetes and weight loss medicines.

Diabetes 283

Diabetes Packaging Drug Pricing Drug Development 283

Pharmaceutical Commerce

AUGUST 16, 2024

By 2026, the first 10 drugs for individuals with Part D coverage—whose medications are mainly used to treat cancer, diabetes, and heart disease—will see discounts off of list prices ranging from 38-79%.

Drug Pricing 98

Drug Pricing Diabetes 98

pharmaphorum

NOVEMBER 21, 2022

Provention Bio has priced its new type 1 diabetes (T1D) prevention therapy Tzield at $13,850 per vial – equivalent to almost $194,000 for its 14-day course – a higher level than had been predicted by industry observers. It also has an option on global marketing rights to the drug.

Diabetes 116

Diabetes Drug Pricing 116

STAT

MAY 24, 2024

Also, the agency’s advisers debate Guardant’s colon cancer liquid biopsy test, and we see new data showing Ozempic’s efficacy in preventing death in diabetes and chronic kidney disease patients. Read the rest…

Diabetes 257

Diabetes Drug Pricing Drug Development 257

STAT

MARCH 15, 2024

Final approval will be contingent on the results of an ongoing study designed to show the drug can improve long-term outcomes for patients. Beyond that timeframe, though, Moody’s expects the prescription drug pricing provisions in the Inflation Reduction Act will more significantly constrain industry growth.

Drug Pricing 239

Drug Pricing Biosimilars Diabetes 239

STAT

JUNE 20, 2024

With the immense demand for GLP-1-based drugs and recurring shortages of the branded treatments, a wide variety of businesses have popped up to offer their own versions of what they claim are GLP-1 drugs. No other company has bid on the contract — to supply 14 million pens for the next three years, at about $2 per pen. The

Diabetes 284

Diabetes Compounding Drug Pricing Drug Development 284

STAT

OCTOBER 31, 2024

In 2016, a number of states filed what eventually became the first in a trio of lawsuits against many of the largest generic companies for allegedly coordinating efforts to fix and maintain prices for dozens of medications to treat a variety of ailments. marketplace had functioned competitively.

Diabetes 331

Diabetes Drug Pricing 331

STAT

JUNE 24, 2024

On top of today’s Alnylam news, we have Congress gearing up to vote on Medicare coverage for multi-cancer screenings and obesity drug coverage. Also, updates on Vertex’s type 1 diabetes cell therapy, and a push for phage therapy. Read the rest…

Diabetes 234

Diabetes Drug Pricing Drug Development 234

STAT

MARCH 14, 2023

list prices for several insulin products by up to 75%, the latest big drugmaker to take such a step in response to a years-long outcry over the cost of the diabetes treatments. The company plans to cut the list price of its NovoLog insulin by 75%, and the prices for Novolin and Levemir by 65% starting in January 2024.

Diabetes 246

Diabetes Drug Pricing 246

STAT

SEPTEMBER 18, 2024

  A Novo Nordisk executive believes that Ozempic, the blockbuster diabetes shot made by the company, is “very likely” to be one of the next drugs targeted for a price cut in bargaining with the Medicare program, Bloomberg News writes. The Inflation Reduction Act, which allows the U.S.

Hospitals 269

Hospitals Drug Pricing Diabetes 269

STAT

OCTOBER 8, 2024

Food and Drug Administration for a “reckless and arbitrary” decision to remove a widely prescribed Eli Lilly drug for combating diabetes and obesity from an official shortages list , STAT tells us. … A trade group representing large compounding pharmacies has sued the U.S. ” A U.S.

Compounding 247

Compounding Compounding Pharmacies Vaccines Immunity 247

STAT

DECEMBER 19, 2024

Although there is a caveat: This particular metric was based on a subset of just three drugs that were deemed to be fairly priced based on a cost-effectiveness assessment — the Mounjaro type 2 diabetes treatment, and the Wegovy and Qsymia obesity drugs. Continue to STAT+ to read the full story…

Department of Veterans Affairs 226

Department of Veterans Affairs Diabetes Drug Pricing 226

STAT

DECEMBER 15, 2022

For people in marginalized and traditionally underserved communities, in which chronic medical conditions such as diabetes, obesity, and respiratory diseases are more widespread, the problem can be the difference between life and death. And for some new medications, it seems the sky’s the limit when it comes to cost.

Diabetes 243

Diabetes Drug Pricing 243

STAT

DECEMBER 15, 2022

In a bid to widen access to insulin in primarily low-income nations in Africa, Eli Lilly has agreed to sell active pharmaceutical ingredients and transfer technology to an Egyptian company that expects to supply the life-saving diabetes treatment to as many as 1 million people by 2030.

Diabetes 264

Diabetes Drug Pricing 264

STAT

NOVEMBER 16, 2022

After a tweet from a fake corporate account last week claimed Eli Lilly would give insulin away for free, the drugmaker’s chief executive officer acknowledged the need to do a better job of widening access to the life-saving diabetes treatment and change perceptions of its existing efforts to do so.

Diabetes 246

Diabetes Drug Pricing 246

STAT

SEPTEMBER 23, 2022

These 22 products compete in nine molecule classes across oncology, rheumatology, diabetes care, and now ophthalmology. As I write this, there are 38 FDA-approved biosimilars ; 22 of them are commercially available. According to the most recent “U.S.

Biosimilars 244

Biosimilars Diabetes Drug Pricing 244

STAT

APRIL 12, 2024

Food and Drug Administration, which in January said it did not find a causal relationship between the class of weight loss and diabetes medications and suicidal ideation. The  The announcement from the European Medicines Agency echoes the findings of a review by the U.S.

Drug Development 240

Drug Development Diabetes Drug Pricing 240